SOURCE: Stock Market Alerts

May 10, 2006 09:50 ET

Emerging Stock Report! May 10, 2006

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts.

MIAMI, FL -- (MARKET WIRE) -- May 10, 2006 -- Stock Market Alert's performance stock list includes: Advanced Cell Technology, Inc. (OTC BB: ACTC), Pfizer Inc (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), & Watson Pharmaceuticals, Inc. (NYSE: WPI).

Advanced Cell Technology, Inc. (OTC BB: ACTC) may be of interest to speculative investors. The company has issued a press release announcing that it has formed an Institutional Review Board ("IRB") and plans to initiate scientific work in the area of Somatic Cell Nuclear Transfer ("SCNT").

This news may get the attention of traders. The formation of the IRB represents a significant milestone for the Company as it achieves two important goals. First, the IRB will review specific scientific work conducted by the Company as required per Massachusetts' new stem cell bill, which came into effect late last year. Secondly, the IRB will review plans for future preclinical testing and clinical trials as the Company moves forward in its therapeutic programs.

The IRB was formulated in January 2006, and is comprised of many experienced and distinguished members. The IRB carefully reviewed the Company's plan to solicit volunteer donors of embryos and oocytes for the SCNT program.

This should be a stock to watch. William Caldwell, CEO of Advanced Cell Technology, said, "We have taken several months to work with our IRB to restart this SCNT program with appropriate and careful planning and oversight. Late last year this entire area was ensconced in significant controversy due to disclosures out of Korea of scientific impropriety. Advanced Cell Technology has long been considered a leader in the area of SCNT. Our scientists now look forward to the opportunity to assist the medical community in validating this important technology platform."

"In the coming years, we hope embryonic stem cell technology will be moving from the laboratory into the clinic," said Robert Lanza, Vice-President of Medical & Scientific Development at ACT. "Although we are learning how to generate various replacement cell types that could be used to treat patients suffering from a long list of diseases, there still remain profound immunological issues. SCNT might eliminate the immune responses associated with the transplantation of these various tissues. Cells resulting from SCNT are not only histocompatible, but they have also been shown to be more youthful, and potentially of greater therapeutic value than adult stem cells."

A profile of Advanced Cell Technology can be found here:

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

Other Stocks of interest:

Pfizer Inc (NYSE: PFE) down 0.1% on 16.5 million shares traded. Pfizer is committed to bringing meaningful improvement to the lives of people living with HIV/AIDS and those at risk around the world.

Johnson & Johnson (NYSE: JNJ) down 0.6% on 7.1 million shares traded. Johnson & Johnson is one of the most comprehensive and broadly based manufacturers of health care products.

Watson Pharmaceuticals, Inc. (NYSE: WPI) down 8.4% on 6.8 million shares traded. Watson Pharmaceuticals, Inc. is one of the leading specialty pharmaceutical companys.

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company received compensation for services performed for Advanced Cell Technology, Inc. (OTC BB: ACTC). The compensation is fourteen thousand dollars from third party, National Financial Communications Corp. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent. The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only. The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer. Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information